Class Action Roundup Lawsuit Filed Over Fraudulent Marketing of Weedkiller in Missouri

|

Bayer and it’s Monsanto subsidiary face a class action lawsuit over Roundup in Missouri, which seeks to refund the cost paid by residents of the state when purchasing the controversial weedkiller, alleging that it was fraudulently marketed as safe, despite known health risks.

The complaint was filed last week in Jackson County Circuit Court, seeking class action status for all Missouri residents who purchased Roundup weed killer products. However, the proposed class specifically excludes individuals pursuing Roundup lawsuits over non-Hodgkins lymphoma or other specific injuries they developed after exposure to the herbicide.

The Missouri plaintiffs allege that Monsanto committed consumer fraud with its marketing and advertising of Roundup products, violating the state’s laws by claiming that Roundup is safe, despite having scientific evidence for decades that indicated Roundup exposure could cause cancer and other health problems.

Roundup-Cancer-Lawsuit-Lawyer
Roundup-Cancer-Lawsuit-Lawyer

On June 25, Bayer sent a response to The Business Journal in St. Louis, responding to a report about the class action Roundup lawsuit, claiming that the the action has no merit, since the active ingredient in the weedkiller was approved by the U.S. Environmental Protection Agency (EPA) as safe.

However, that assessment is under a cloud, following the release of documents known as the โ€œMonsanto Papers,โ€ which were uncovered during ongoing litigation against the company and suggest that Monsanto exercised undue influence over the EPA and European regulators.

Documents detailed how Monsanto employees and lobbyists were able to call up EPA officials and potentially have safety reviews altered or even cancelled. Monsanto also was the ghost-writer behind several supposedly independent Roundup safety studies and actually wrote part of a safety review that was supposedly written by European regulators.

Those revelations, and the science presented in recent trials involving claims brought by individuals diagnosed with non-Hodgkins lymphoma from Roundup, have resulted in several different juries finding that the manufacturer knew or should have known about the cancer risk, and withheld information. In three trials over the past year, Bayer has suffered devastating losses, including large punitive damage awards designed to punish the company for the actions of its Monsanto unit.

The first trial was held in California state court last summer, ending in aย $289 million jury verdict, which was later reduced to a final judgment of aboutย $78 millionย following post-trial motions.

A second trial was held in federal court earlier this year, resulting in a verdict ofย $80 million, despite a format that was widely thought to heavily favor the manufacturer.

Finally, a third trial concluded last month with aย landmark $2 billion verdictย in California state court, after considering evidence in a lawsuit brought by a husband and wife who were each diagnosed with non-Hodgkins lymphoma following use of Roundup.

Bayer faces more than 15,000 other claims brought by individuals nationwide. While the cases are being managed during pretrial proceedings in a manner similar to a class action, each of the complaints involve individual damages and the manufacturer may face thousands of separate trials if Roundup settlements or another resolution is not reached.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Image Credit: Photo Courtesy of <a href="https://www.flickr.com/photos/jeepersmedia/14873964648/in/photolist-oEmXum-oEn9ki-oWRbVK-oEmWnm-oWzFRi-oWPp5q-oEmvVY-oEmahn-oEmb2Z-r4HEKx-qrgbpD-qr3Syo-qrgb6x-r4HT7B-qrg5px-r6sNDC-rnWUhU-rnV1kP-qr3DSm-rnWEWf-qrfS4a-qk19Pd-argEhZ-7xtMSn-ettS6G-qk2CQb-qnhf96-pqi9cy-8CVPxp-pqwwpc-smqxZX-sjb3fb-7xtMYM-q5QsjF-rinfWJ-qndT8S-pqwisv-pqhREq-qndxjo-qn6XWT-q5Hp19-q5JaP9-q5J8Wm-q5HsUG-qngP1k-qn6VRF-fj2VwZ-cnzyy9-seffn5-rV4Khp">Mike Mozart via Flickr</a> Creative Commons



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

An Illinois woman has joined a growing number of plaintiffs alleging that the Medtronic Intellis neurostimulator, and similar devices, may fail to relieve chronic pain and instead lead to worsening complications.
A federal judge is being asked to certify seven hair relaxer class action lawsuits seeking medical monitoring for users, following studies that link the products to an increased risk of cancer.